Get the Stockscreener App
26.24
2.05%
-0.55
Pre-market:
27.00
0.76
+2.90%
Ideaya Biosciences Inc stock is traded at $26.24, with a volume of 1.31M.
It is down -2.05% in the last 24 hours and up +6.19% over the past month.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
See More
Previous Close:
$26.79
Open:
$26.89
24h Volume:
1.31M
Relative Volume:
1.16
Market Cap:
$2.30B
Revenue:
$23.38M
Net Income/Loss:
$-155.22M
P/E Ratio:
-11.98
EPS:
-2.19
Net Cash Flow:
$-134.36M
1W Performance:
-5.07%
1M Performance:
+6.19%
6M Performance:
+66.39%
1Y Performance:
-13.11%
1-Day Range:
$26.05
$26.96
1-Week Range:
$26.05
$28.39
52-Week Range:
$13.45
$32.67
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Name
Ideaya Biosciences Inc
Sector
Industry
Phone
650-443-6209
Address
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
26.24 | 2.35B | 23.38M | -155.22M | -134.36M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Initiated | Guggenheim | Buy |
| Sep-04-25 | Initiated | Barclays | Overweight |
| Sep-04-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-22-25 | Initiated | TD Cowen | Buy |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Jun-26-25 | Initiated | Wells Fargo | Overweight |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Nov-05-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-15-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-08-24 | Initiated | Mizuho | Outperform |
| Mar-08-24 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | SVB Securities | Outperform |
| May-24-23 | Initiated | Goldman | Buy |
| Apr-24-23 | Upgrade | Stifel | Hold → Buy |
| Mar-23-23 | Initiated | Berenberg | Buy |
| Feb-28-23 | Initiated | RBC Capital Mkts | Outperform |
| Dec-28-22 | Initiated | CapitalOne | Overweight |
| Oct-27-22 | Initiated | Citigroup | Buy |
| Aug-15-22 | Downgrade | Stifel | Buy → Hold |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-10-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Mar-11-21 | Initiated | Guggenheim | Buy |
| Oct-07-20 | Initiated | Wedbush | Outperform |
| Sep-01-20 | Initiated | Northland Capital | Outperform |
| Jul-13-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-17-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-06-20 | Initiated | H.C. Wainwright | Buy |
| Mar-13-20 | Initiated | ROTH Capital | Buy |
| Oct-17-19 | Initiated | Oppenheimer | Outperform |
| Sep-10-19 | Initiated | Robert W. Baird | Outperform |
| Jun-17-19 | Initiated | Citigroup | Buy |
| Jun-17-19 | Initiated | JP Morgan | Neutral |
| Jun-17-19 | Initiated | Jefferies | Buy |
View All
Ideaya Biosciences Inc Stock (IDYA) Latest News
Is IDEAYA Biosciences Inc. forming a reversal patternPortfolio Gains Summary & Community Consensus Picks - newser.com
Is IDEAYA Biosciences Inc. stock in correction or buying zoneWeekly Stock Summary & AI Forecast Swing Trade Picks - newser.com
IDEAYA Biosciences Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Can IDEAYA Biosciences Inc. stock maintain growth trajectoryTrade Volume Report & Free Weekly Chart Analysis and Trade Guides - newser.com
Is IDEAYA Biosciences Inc. showing signs of accumulationJuly 2025 Sentiment & Expert Curated Trade Ideas - newser.com
Has IDEAYA Biosciences Inc. formed a bullish divergenceStop Loss & Weekly Top Stock Performers List - newser.com
IDEAYA Biosciences' (IDYA) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
J.P. Morgan Remains Bullish on IDEAYA Biosciences (IDYA) - Yahoo
Ideaya Biosciences stock maintains Market Outperform rating at Citizens - Investing.com
How IDEAYA Biosciences Inc. (30J) stock compares with market leaders2025 Trade Ideas & Technical Confirmation Trade Alerts - newser.com
IDEAYA Biosciences Inc. stock outlook for YEARTrade Volume Report & Reliable Intraday Trade Alerts - newser.com
IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss - MSN
Is IDEAYA Biosciences Inc. stock bottoming outPrice Action & Weekly Market Pulse Alerts - newser.com
Can momentum traders help lift IDEAYA Biosciences Inc.July 2025 Weekly Recap & Safe Swing Trade Setups - newser.com
IDEAYA Biosciences (NASDAQ:IDYA) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Price action breakdown for IDEAYA Biosciences Inc.July 2025 Trade Ideas & AI Based Buy and Sell Signals - newser.com
Using Bollinger Bands to evaluate IDEAYA Biosciences Inc.CEO Change & Weekly Momentum Picks - newser.com
Will IDEAYA Biosciences Inc. stock split again soonInflation Watch & Technical Pattern Alert System - newser.com
Long term hold vs stop loss in IDEAYA Biosciences Inc.2025 Risk Factors & AI Based Buy and Sell Signals - newser.com
Platinum Investment Management Ltd. Has $3.51 Million Stake in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
Combining price and volume data for IDEAYA Biosciences Inc.Weekly Stock Summary & Daily Volume Surge Signals - newser.com
IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events - 富途牛牛
What to do if you’re stuck in IDEAYA Biosciences Inc.M&A Rumor & Fast Entry High Yield Stock Tips - newser.com
What drives IDEAYA Biosciences Inc stock priceHealthcare Stock Analysis & Minimal Investment Trading Plans - earlytimes.in
Voya Investment Management LLC Has $377,000 Stock Position in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Eastern Progress
IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events - The Malaysian Reserve
Ideaya Biosciences announces inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
JPMorgan Anticipates Positive Developments for Ideaya Biosciences (IDYA) - GuruFocus
J.P. Morgan Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $74 - 富途牛牛
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
UBS reiterates Buy rating on Ideaya Biosciences stock with $50 target - Investing.com
Ideaya Biosciences Inc Stock (IDYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):